|
|
| | Zansecimab Basic information |
| Product Name: | Zansecimab | | Synonyms: | Zansecimab;Research Grade Zansecimab (DHA42304);Zansecimab (anti-ANGPT2);Research Grade Zansecimab | | CAS: | 2415205-37-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Zansecimab Structure]() |
| | Zansecimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Zansecimab Usage And Synthesis |
| Uses | Zansecimab (LY-3127804) is an immunoglobulin G4-kappa, a monoclonal antibody against angiopoietin 2 (Ang 2). Zansecimab has potential applications in angiogenesis and immune regulation[1][2][3]. | | References | [1] Yen CC, et al. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf. 2022 Feb;21(2):157-166. DOI:10.1080/14740338.2022.1995353
[2] Wang Y, et al. Angiogenesis as a potential treatment strategy for rheumatoid arthritis. Eur J Pharmacol. 2021 Nov 5;910:174500. DOI:10.1016/j.ejphar.2021.174500 |
| | Zansecimab Preparation Products And Raw materials |
|